Persistent pain after resolution of clinically appreciable signs of arthritis poses a therapeutic challenge, and immunosuppressive therapies do not meet this medical need. To investigate this conversion to persistent pain, we utilized the K/BxN serum transfer arthritis model, which has persistent mechanical hypersensitivity despite the resolution of visible inflammation. Toll-like receptor (TLR) 4 has been implicated as a potential therapeutic target in neuropathic and other pain models. We compared the relative courses of serum transfer arthritis and mechanical hypersensitivity in wild type (WT) and Tlr4 À/À mice. K/ BxN serum transfer induced similar joint swelling and inflammation from days 4-22 in WT and Tlr4 À/À mice. Unlike WT mice, Tlr4 À/À mice displayed a significant reversal in mechanical hypersensitivity and diminished appearance of glial activation markers after resolution of peripheral inflammation. Intrathecal (IT) delivery of a TLR4 antagonist, lipopolysaccharide Rhodobacter sphaeroides (LPS-RS; 10 lg), on days 6, 9, and 12 abrogated the transition to persistent mechanical hypersensitivity in WT arthritic mice, while later administration had no impact. We utilized a lipidomics liquid chromatography tandem mass spectrometry methodology to determine spinal cord profiles of bioactive lipid species after early LPS-RS treatment compared to vehicle-treated control animals. WT arthritic mice had reduced spinal levels of the anti-inflammatory prostaglandin 15-deoxy-D 12,14 -PGJ 2 (15d-PGJ 2 ) on day 6, compared to IT LPS-RS-treated mice. Direct IT application of 15d-PGJ 2 (0.5 lg) on day 6 improved mechanical hypersensitivity in arthritic mice within 15 min. Hence, TLR4 signaling altered spinal bioactive lipid profiles in the serum transfer model and played a critical role in the transition from acute to chronic postinflammatory mechanical hypersensitivity. Ó
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Introduction
Despite the efficacy of new small molecule and biologic treatment strategies in inflammatory arthritis, pain remains a significant clinical issue and can persist after resolution of joint swelling [46] . Residual pain might be due to incompletely treated subclinical inflammation or irreversible articular tissue damage. Postinflammatory pain might also be the result of a facilitated state of nociceptive processing at the level of the spinal dorsal horn, which would compel a separate therapeutic approach [44] . The presence of toll-like receptors (TLRs) in the spinal cord suggests the presence of central endogenous activators that could influence spinal nociceptive processing.
Amongst the TLRs, TLR4 has been described as a contributing receptor to both neuropathic pain and the perpetuation of peripheral joint inflammation in murine models of arthritis. TLR4 is extensively expressed on spinal microglia [24] , astrocytes [7] , and certain small primary afferent neurons [49] . Nonneuronal cells are critical in the development of facilitated pain states after inflammation and nerve injury (reviewed in [20, 29, 42, 48] ). In addition, nerve injury induced hypersensitivity is attenuated in Tlr4 À/À mice and in mice treated with spinal TLR4 oligonucleotides [22, 45] . Thus, while the TLRs were originally described according to their ability to respond to exogenous microbial products there is sufficient literature to suggest endogenous products activating TLRs during sterile inflammation. Prior work suggests that TLR4 
